BenevolentAI Bio — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BEN-2001This phase 2b study is designed as multicentre, multinational, randomized, double blind, parallel group and placebo controlled with three doses of Bavisant (0.5, 1, and 3 mg/d) in subjects with excessive daytime sleepiness with Parkinson's disease.	SEP	Phase 2	À vérifier	United States	À vérifier
BEN-2001This phase 2b study is designed as multicentre, multinational, randomized, double blind, parallel group and placebo controlled with three doses of Bavisant (0.5, 1, and 3 mg/d) in subjects with excessive daytime sleepiness with Parkinson's disease.	SEP	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
BEN-2001	SEP	Phase 2	NCT03194217	CASPAR — BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.